Our study has highlighted that pre-treatment PNI represents a prognostic and available low-cost biomarker in recurrent or unresectable HCC patients treated with ICIs therapy, whether in anti-PD1 combination therapy or in anti-PD1 monotherapy. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.